HCAR 3
Alternative Names: HCAR-3Latest Information Update: 20 Aug 2024
At a glance
- Originator ImmunoACT
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Glioblastoma; Neuroblastoma
Most Recent Events
- 19 Mar 2024 ImmnuoACT plans a pivotal phase II trial for Neuroblastoma and Glioblastoma in 2027 (Parenteral) (ImmunoACT pipeline, March 2024)
- 19 Mar 2024 HCAR 3 is available for licensing as of 19 Mar 2024. https://www.immunoact.com/copy-of-nexcar19, prior to March 2024 (ImmunoACT pipeline, March 2024)
- 19 Mar 2024 Preclinical trials in Glioblastoma in India (Parenteral), prior to March 2023 (ImmunoACT pipeline, March 2024)